A Cross-Sectional Survey Study of Cannabis Use for Fibromyalgia Symptom Management

Mayo Clin Proc. 2024 Apr;99(4):542-550. doi: 10.1016/j.mayocp.2023.12.018.

Abstract

Objective: To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia.

Patients and methods: An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia.

Results: Of 5234 patients with fibromyalgia sent the online survey, 1336 (25.5%) responded and met the inclusion criteria. Survey respondents had a median age of 48 (Q1-Q3: 37.5-58.0) years, and most identified as female. Nearly half of respondents (49.5%, n=661) reported cannabis use since their fibromyalgia diagnosis. The most common symptoms for which respondents reported using cannabis were pain (98.9%, n=654); fatigue (96.2%; n=636); stress, anxiety, or depression (93.9%; n=621); and insomnia (93.6%; n=619). Improvement in pain symptoms with cannabis use was reported by 82.0% (n=536). Most cannabis-using respondents reported that cannabis also improved symptoms of stress, anxiety, and depression and of insomnia.

Conclusion: Considering that cannabis is a popular choice among patients for managing fibromyalgia symptoms, clinicians should have adequate knowledge of cannabis when discussing therapeutic options for fibromyalgia with their patients.

MeSH terms

  • Adult
  • Cannabis*
  • Cross-Sectional Studies
  • Female
  • Fibromyalgia* / diagnosis
  • Fibromyalgia* / therapy
  • Humans
  • Middle Aged
  • Pain
  • Sleep Initiation and Maintenance Disorders* / diagnosis
  • Sleep Initiation and Maintenance Disorders* / etiology
  • Sleep Initiation and Maintenance Disorders* / therapy
  • Surveys and Questionnaires